NEW YORK, July 27, 2015 /PRNewswire/ -- Attorney
Advertising-- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of AMAG Pharmaceuticals Inc. ("AMAG" or the "Company")
(NasdaqGM: AMAG -News). Such investors are advised to contact
Peretz Bronstein or his investor
relations coordinator Eitan Kimelman
at info@bgandg.com or 212-697-6484.
The investigation concerns whether AMAG and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On July 27, 2015, the Company
stated in its 10Q report that "On July 20,
2015, the Federal Trade Commission (the "FTC") notified us
that it is conducting an investigation with respect to
Makena or any hydroxyprogesterone caproate product. The FTC
noted that the existence of the investigation does not indicate
that the FTC has concluded that Lumara Health or its predecessor
has violated the law. We intend to cooperate with the FTC
investigation and at this time we cannot assess potential outcomes
of this investigation."
Following this news, shares of AMAG fell $5.58 or 7.92%, during intraday trading to trade
at at $64.86 on July 27, 2015.
If you are aware of any facts relating to this investigation, or
purchased shares of AMAG, you can assist this investigation by
contacting Peretz Bronstein or his
Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-amag-pharmaceuticals-inc-300119134.html
SOURCE Bronstein, Gewirtz & Grossman, LLC